Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
RESEARCH TOOLSreports
CATX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $19.05
Previous CloseN/A
Volume311.62K
Average Volume (3M)799.63K
Market Cap
$143.66M
Enterprise Value$2.59M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 14, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding74,051,840
10 Day Avg. Volume1,065,940
30 Day Avg. Volume799,635
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)139.61
Price to Cash Flow (P/CF)12.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.80
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$14.20Price Target Upside563.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's recommendation includes a Buy rating and a 12-month price target of $10.
Clinical Trials ProgressEnrollment in the ongoing Phase I/IIa trial of lead asset Pb-212-VMT-α-NET in SSTR2+ NETs has picked up with a total of 30 patients treated, indicating progress in clinical trials.
Financial StabilityPerspective ended 2024 with ~$227M in cash, cash equivalents, and marketable securities, which should provide a runway into late 2026.
Bears Say
Clinical Trial ChallengesVMT01 Demonstrated Limited Monotherapy Activity in the First Two Cohorts.
Financial PerformanceA net loss of $1.22 per share was reported for 2024, significantly wider than the prior estimated net loss of $0.32 per share.
Risks And UncertaintiesRisks include negative clinical results with the lead asset, delays in advancing pipeline candidates, inability to obtain regulatory approvals, competitive risks, and long-term dilution risk.
---
Ownership Overview
2.64% Insiders
18.53% Mutual Funds
0.18% Other Institutional Investors
73.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CATX FAQ
What was Perspective Therapeutics’s price range in the past 12 months?
Perspective Therapeutics lowest stock price was $1.60 and its highest was $19.05 in the past 12 months.
What is Perspective Therapeutics’s market cap?
Perspective Therapeutics’s market cap is $143.66M.
When is Perspective Therapeutics’s upcoming earnings report date?
Perspective Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 21 days.
How were Perspective Therapeutics’s earnings last quarter?
Perspective Therapeutics released its earnings results on Mar 26, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.268 by -$0.302.
Is Perspective Therapeutics overvalued?
According to Wall Street analysts Perspective Therapeutics’s price is currently Undervalued.
Does Perspective Therapeutics pay dividends?
Perspective Therapeutics does not currently pay dividends.
What is Perspective Therapeutics’s EPS estimate?
Perspective Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Perspective Therapeutics have?
Perspective Therapeutics has 74,051,840 shares outstanding.
What happened to Perspective Therapeutics’s price movement after its last earnings report?
Perspective Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.268. Following the earnings report the stock price went up 1.322%.
Which hedge fund is a major shareholder of Perspective Therapeutics?
Currently, no hedge funds are holding shares in CATX
---
Perspective Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.20 (563.55% Upside)
$14.20 (563.55% Upside)
Blogger Sentiment
Bullish
CATX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $316.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 22.8%
Last 30 Days ▲ 22.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.20%
12-Months-Change
Fundamentals
Return on Equity
-19.42%
Trailing 12-Months
Asset Growth
253.93%
Trailing 12-Months
Company Description
Perspective Therapeutics
Perspective Therapeutics (CATX) is a biotechnology company focused on developing innovative therapeutic solutions within the healthcare sector. The company specializes in the research, development, and commercialization of cutting-edge treatments aimed at addressing complex medical conditions. Their core products and services include advanced therapeutics and technologies designed to improve patient outcomes and enhance the effectiveness of existing treatment regimens.
---
CATX Stock 12 Month Forecast
Average Price Target
$14.20
▲(563.55% Upside)
Technical Analysis
Best Analysts Covering CATX
1 Year
1 Year Success Rate
4/14 ratings generated profit
1 Year Average Return
-2.00%
reiterated a buy rating 28 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -2.00% per trade.
---